KR101047796B1 - Cold grass extract having an effect of improving insulin resistance and a product containing the same as an active ingredient - Google Patents

Cold grass extract having an effect of improving insulin resistance and a product containing the same as an active ingredient Download PDF

Info

Publication number
KR101047796B1
KR101047796B1 KR1020080119631A KR20080119631A KR101047796B1 KR 101047796 B1 KR101047796 B1 KR 101047796B1 KR 1020080119631 A KR1020080119631 A KR 1020080119631A KR 20080119631 A KR20080119631 A KR 20080119631A KR 101047796 B1 KR101047796 B1 KR 101047796B1
Authority
KR
South Korea
Prior art keywords
ethanol extract
cold
insulin resistance
protein
socs
Prior art date
Application number
KR1020080119631A
Other languages
Korean (ko)
Other versions
KR20100060857A (en
Inventor
명길선
이정희
허철성
Original Assignee
주식회사한국야쿠르트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사한국야쿠르트 filed Critical 주식회사한국야쿠르트
Priority to KR1020080119631A priority Critical patent/KR101047796B1/en
Publication of KR20100060857A publication Critical patent/KR20100060857A/en
Application granted granted Critical
Publication of KR101047796B1 publication Critical patent/KR101047796B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/80Scrophulariaceae (Figwort family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

본 발명은 냉초 에탄올 추출물 및 이를 유효성분으로 함유하는 제품에 관한 것으로서, 본 발명의 냉초 에탄올 추출물은 지방세포의 SOCS-3 단백질의 발현을 억제하여 인슐린 저항성을 개선하고, 혈당을 강하시키며, 체지방 및 체중 증가를 억제하는 효능을 갖고 있어 대사증후군 예방과 치료를 위한 의약품 또는 건강기능식품으로 유용하게 이용될 수 있다.The present invention relates to a cold grass ethanol extract and a product containing the same as an active ingredient, the cold grass ethanol extract of the present invention inhibits the expression of SOCS-3 protein of adipocytes to improve insulin resistance, lower blood sugar, body fat and Since it has the effect of inhibiting weight gain, it can be usefully used as a medicine or a functional food for preventing and treating metabolic syndrome.

인슐린저항성, 냉초(冷草, Veronicastrum sibiricum), 당뇨, 비만, 대사증후군, SOCS-3 단백질 Insulin resistance, cold grass (Veronicastrum sibiricum), diabetes, obesity, metabolic syndrome, SOCS-3 protein

Description

인슐린 저항성 개선 효능을 갖는 냉초 추출물 및 이를 유효성분으로 함유하는 제품{Veronicastrum sibiricum extracts for improving insulin resistance and products containing them as effective ingredient}{Veronicastrum sibiricum extracts for improving insulin resistance and products containing them as effective ingredient}

본 발명은 냉초 에탄올 추출물 및 이를 유효성분으로 함유하는 제품에 관한 것으로서, 보다 상세하게는 지방세포의 SOCS-3 단백질의 발현을 억제하여 인슐린 저항성을 개선하고, 혈당을 강하시키며, 체지방 및 체중 증가를 억제하는 효능을 갖는 냉초 에탄올 추출물 및 이를 유효성분으로 함유하는 대사증후군 예방 및 치료용 약학조성물, 발효유, 음료 및 기능성 식품에 관한 것이다.The present invention relates to a cold grass ethanol extract and a product containing the same as an active ingredient, and more particularly, to inhibit the expression of SOCS-3 protein of adipocytes to improve insulin resistance, lower blood sugar, increase body fat and weight gain. It relates to a cold ethanol extract having an inhibitory effect and a pharmaceutical composition for preventing and treating metabolic syndrome containing the same as an active ingredient, fermented milk, beverages and functional foods.

인슐린 저항성이란 인슐린이 혈액을 통해 목표조직으로 이동하여 작용하였으나 목표조직에서 반응이 일어나지 않는 증상으로 인슐린의 주요 역할인 혈당강하와 지방분해가 일어나지 않아 당과 지방의 항상성 유지가 무너지는 증상이다. 따라서 인슐린 저항성을 보이는 사람은 혈당이 높고 혈중에 인슐린양이 높게 유지된다. 이러한 증상이 계속되면 지방세포에서 지방분해가 계속적으로 일어나고 근육에서 당 흡수가 일어나지 않으며 간에서 당 생성이 일어난다. 결국은 인슐린 저항성이 지속되며 비만과 지방간, 당뇨 등으로 진행된다. 인슐린 저항성의 원인으로는 과잉섭취, 운동부족, 노화, 흡연, 또는 약물 부작용 등을 들 수 있다. 최근에는 이러한 인슐린 저항성을 개선하기 위한 많은 연구가 진행되고 있다. Insulin resistance is a condition in which insulin moves through the blood to target tissues, but no reaction occurs in the target tissues, and the main role of insulin is to lower blood sugar and lipolysis. Therefore, those who show insulin resistance have high blood sugar and high insulin levels in the blood. If these symptoms persist, lipolysis continues in fat cells, glucose uptake does not occur in muscles, and glucose production occurs in the liver. Eventually, insulin resistance continues and progresses to obesity, fatty liver and diabetes. Causes of insulin resistance include excessive intake, lack of exercise, aging, smoking, or drug side effects. In recent years, many studies have been conducted to improve such insulin resistance.

SOCS 단백질(suppressor of cytokine signaling protein)은 사이토카인(cytokine) 신호전달 저해물질로 인슐린을 비롯한 다양한 신호전달 물질들에 의해 발현되며 이들의 작용을 적정하게 중지하는 역할을 한다. 인슐린은 혈액을 통해 세포에 전달되었을 때 세포막에 인슐린 수용체(insulin receptor)에 결합하고 이 수용체의 세포 내부로 하위체(insulin receptor subunit-1, IRS-1)가 있어 세포 내로 신호가 전달되는데 SOCS 단백질, 특히 지방세포에서는 SOCS-3 단백질이 인슐린 수용체의 활성화를 저해하고 인슐린 수용체 하위체(IRS-1)의 분해를 유도해 인슐린신호 전달을 중지하게 된다(K. Egawa et al., Endocrinology 141 (2000) 1930-1935, R. Zhande et al., Mol Cell Biol 24 (2004) 8929-8937). SOCS-3 단백질은 ob/ob 또는 db/db 쥐 등 비만과 당뇨 모델 동물의 지방조직에서 과발현 되어 있어 SOCS-3 단백질이 인슐린 저항성과 깊은 관련이 있음이 증명되었다(Emanuelli B et al., J Biol Chem 276 (2001) 47944-47949). 또한 유전적인 조작이 아니라 고지방식이를 먹여 비만을 유도한 쥐에서도 이와 같은 결과를 보여 비만인 경우 SOCS-3 단백질이 과발현되어 있고 인슐린 저항성 발생의 주요 원인이 됨이 밝혀졌다(Ueki K et al., Proc Natl Acad Sci USA (2004) 10422-10427).SOCS protein (suppressor of cytokine signaling protein) is a cytokine signaling inhibitor and is expressed by various signaling agents including insulin and plays an appropriate role in stopping their action. When insulin is delivered to cells through the blood, insulin binds to the insulin receptor on the cell membrane, and there is an insulin receptor subunit-1 (IRS-1) inside the cell that carries signals into the cell. In particular, in adipocytes, SOCS-3 protein inhibits the activation of insulin receptors and induces the breakdown of insulin receptor sub-types (IRS-1), which disrupts insulin signal transduction (K. Egawa et al., Endocrinology 141 (2000). 1930-1935, R. Zhande et al., Mol Cell Biol 24 (2004) 8929-8937). SOCS-3 protein is overexpressed in adipose tissues of obese and diabetic model animals such as ob / ob or db / db mice, demonstrating that SOCS-3 protein is closely related to insulin resistance (Emanuelli B et al., J Biol Chem 276 (2001) 47944-47949). In addition, the rats inducing obesity by feeding high-fat diet and not by genetic manipulation showed that SOCS-3 protein is overexpressed and is a major cause of insulin resistance in obesity (Ueki K et al., Proc Natl Acad Sci USA (2004) 10422-10427).

한편, 냉초(冷草 , Veronicastrum sibiricum)는 현삼과의 여러해살이풀로 어린 순은 나물로 먹으며 생약으로는 뿌리를 말린 것을 이용한다. 대하증, 각기, 류머티즘, 관절염, 건위, 거담, 편두통, 수종, 이뇨, 통경, 중풍, 변비에 사용되었다. 또한 감기에 해열작용이 있으며 속병의 통증과 부인과, 순환계 질환을 다스리는데 이용되어 왔다. 뿌리에는 사포닌, 전초에는 쿠마린, 아스코르빈산, 알칼로이드가 있다고 알려져 있으며 식품원료로 사용이 가능하도록 식품공전에도 등록되어(2002년 8월 2일) 법적인 보호를 받고 있다. 현재 국내에는 대한민국 특허등록 제0512322호에서 냉초추출물을 함유하는 찜질용 패치제와 대한민국 특허등록 제0512322호에서 냉초 추출물의 변비개선효과에 대한 효능에 대하여 특허를 받았으며 생약학회지 등에 냉초의 성분을 분석한 논문(이숙연 등, 생약학회지 19 (1988) 34-38)이 있으나 냉초 추출물이 인슐린 저항성 개선이나 혈당 강하에 효과가 있다는 사실은 어느 문헌에도 어떠한 개시나 교시된 바도 없다.On the other hand, cold grass (冷 草, Veronicastrum sibiricum ) is a perennial herb of Hyunsamaceae, eaten as young sprouts and herbs, and dried roots are used as a herbal medicine. Hypothalamus, each, rheumatism, arthritis, dry stomach, expectorant, migraine, edema, diuresis, pain, paralysis, constipation. It also has antipyretic effects on the common cold and has been used to control pain, gynecology and circulatory diseases. The roots are known to contain saponins, and outposts have coumarin, ascorbic acid and alkaloids. They are registered in the Food Code (August 2, 2002) for legal use as food ingredients. At present, in Korea, patents for cold water extracts containing cold grass extracts in Korea Patent Registration No. 0512322 and patents on the efficacy of constipation improvement effect of cold grass extracts in Korea Patent Registration No. 0512322 have been analyzed and analyzed components of cold grass etc. Although there is a paper (Sook-Yeon Lee et al., 19 (1988) 34-38), the fact that cold tea extract is effective in improving insulin resistance or lowering blood sugar has not been disclosed or taught in any literature.

이에 본 발명자들은 200여종의 천연물 추출물 중 냉초(冷草 , Veronicastrum sibiricum)의 에탄올 추출물이 지방세포에서 SOCS-3 단백질의 발현을 저해하여 인슐린의 신호전달을 유지시키고 인슐린 저항성을 개선하는 효과를 확인하고 동물실험을 통해 혈당강하효과와 항비만효과를 검증하고 본 발명을 완성하게 되었다.In this regard, the present inventors confirmed the effect of ethanol extract of cold grass ( Veronicastrum sibiricum ) among 200 kinds of natural extracts to inhibit the expression of SOCS-3 protein in adipocytes to maintain insulin signaling and improve insulin resistance. Through animal experiments, the hypoglycemic effect and the anti-obesity effect were verified and the present invention was completed.

이에, 본 발명은 지방세포의 SOCS-3 단백질의 발현을 억제하여 인슐린 저항성 을 개선하고, 혈당을 강하 시키며, 체지방 및 체중 증가를 억제하는 효능을 갖는 냉초 에탄올 추출물 및 이를 유효성분으로 함유하는 대사증후군 예방 및 치료용 약학 조성물, 발효유, 음료 및 건강기능식품을 제공하는 것을 목적으로 한다.Accordingly, the present invention improves insulin resistance by inhibiting the expression of SOCS-3 protein in adipocytes, lowers blood sugar, inhibits body fat and weight gain, and cold ethanol extract and metabolic syndrome containing the same as an active ingredient. An object of the present invention is to provide a prophylactic and therapeutic pharmaceutical composition, fermented milk, a beverage and a dietary supplement.

상기와 같은 목적을 달성하기 위하여, 본 발명은 지방세포의 SOCS-3 단백질의 발현을 억제하여 인슐린의 신호전달을 원활히 하고, 혈당을 낮추며 비만을 억제하는 효능을 갖는 냉초 에탄올 추출물 및 이를 유효성분으로 함유하는 대사증후군 예방 및 치료용 약학 조성물, 발효유, 음료 및 건강기능식품을 제공하는 것을 특징으로 한다.In order to achieve the above object, the present invention is to inhibit the expression of SOCS-3 protein of adipocytes to facilitate the signaling of insulin, lowering blood sugar and inhibiting obesity as cold ethanol extract and an effective ingredient It is characterized by providing a pharmaceutical composition for the prevention and treatment of metabolic syndrome containing, fermented milk, beverages and health functional food.

이하 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.

본 발명의 냉초의 에탄올 추출물은 냉초의 뿌리부분을 모아 건조시킨 후, 파쇄하고 단위 질량당(kg) 1L의 50% 에탄올을 첨가하여 상온에서 7일 정도 반응시켜 냉초 추출액을 얻은 다음, 여과지에 거른 후 동결건조하여 분말화하여 제조한다.The ethanol extract of the cold grass of the present invention is collected by drying the roots of the cold grass, crushed and added to 1L 50% ethanol per unit mass (kg) to react at room temperature for 7 days to obtain a cold grass extract, then filtered through a filter paper After lyophilization to prepare a powder.

또한, 본 발명의 상기의 냉초 에탄올 추출물을 유효성분으로 포함하는 대사증후군 예방 및 치료용 조성물은 실제 임상 투여 시에 경구의 여러 가지 제형으로 투여될 수 있는데, 제제화 할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여 를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기의 냉초 에탄올 추출물에 적어도 하나 이상의 부형제, 예를 들면, 전분, 덱스트린(dextrin), 칼슘카보네이트(Calcium carbonate), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘, 스티아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데, 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면, 습윤제, 감미제, 방향제, 보존제 들이 포함될 수 있다.In addition, the composition for the prevention and treatment of metabolic syndrome comprising the cold ethanol extract of the present invention as an active ingredient can be administered in various oral dosage forms at the time of actual clinical administration, when formulated, commonly used fillers, extenders , Diluents or excipients such as binders, wetting agents, disintegrants, surfactants and the like. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, dextrin, and calcium carbonate in the cold ethanol extract. (Calcium carbonate), gelatin, etc. are mixed and prepared. In addition to simple excipients, lubricants such as magnesium, stiarate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. have.

상기의 대사증후군 예방 및 치료용 조성물의 통상적인 1일 투여량은 100 내지 1,000mg/kg 체중, 바람직하게는 200 내지 500 mg/kg 체중의 범위이고, 1회 또는 수회로 나누어 투여할 수 있다. 그러나 활성성분의 실제 투여량은 투여경로, 환자의 연령, 성별, 체중 및 환자의 중증도 등의 여러 관련 인자에 비추어 결정되어야 하는 것으로서 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.A typical daily dosage of the composition for preventing and treating metabolic syndrome is in the range of 100 to 1,000 mg / kg body weight, preferably 200 to 500 mg / kg body weight, and may be administered once or in several divided doses. However, the actual dosage of the active ingredient should be determined in view of several related factors such as the route of administration, the age, sex, weight of the patient and the severity of the patient, and the dosage does not limit the scope of the present invention in any aspect.

또한, 본 발명에 따른 냉초 에탄올 추출물은 독성 및 부작용이 거의 없으므로 예방 목적으로 복용 시에도 안심하고 사용할 수 있다.In addition, cold ethanol extract according to the present invention can be used with confidence even when taking for the purpose of prevention because there is little toxicity and side effects.

한편, 본 발명의 냉초 에탄올 추출물을 유효성분으로 함유하는 발효유는 유산균 배양액과 냉초 에탄올 추출물 동결 건조 분말 및 혼합과즙시럽을 일정비율로 조합하여 150bar에서 균질한 후 10℃ 이하로 냉각한 후 용기에 포장하여 발효유를 제조한다.On the other hand, the fermented milk containing the cold ethanol extract of the present invention as an active ingredient is a lactic acid bacteria culture medium, cold grass ethanol extract lyophilized powder and mixed fruit syrup combined at a constant rate at 150 bar and then cooled to 10 ℃ or less and packed in a container To prepare fermented milk.

한편, 본 발명의 냉초 에탄올 추출물을 유효성분으로 함유하는 음료는 혼합과즙시럽, 냉초 에탄올 추출물 동결 건조 분말 및 물을 일정한 비율로 조합하여 150bar에서 균질한 후 10℃ 이하로 냉각한 후 유리병, 패트병 등 소포장 용기에 포장하여 기능성 음료를 제조한다.On the other hand, the beverage containing the cold ethanol extract of the present invention as an active ingredient is a mixture of fruit juice syrup, cold ethanol extract lyophilized powder and water in a uniform ratio and homogenized at 150 bar and then cooled to below 10 ℃ glass bottles, plastic bottles Functional beverages are prepared by packaging in small packaging containers.

한편, 본 발명의 냉초 에탄올 추출물을 유효성분으로 함유하는 건강기능식품은 상기 냉초 에탄올 추출물 동결 건조 분말을 포함하는 것 이외에 영양보조성분으로서 비타민 B1, B2, B5, B6, E 및 초산에스테르, 니코틴산 아미드, 올리고당 등이 첨가될 수 있으며 여타의 식품 첨가물이 첨가되어도 무방하다.On the other hand, the health functional food containing the cold ethanol extract of the present invention as an active ingredient, in addition to the cold ethanol extract freeze-dried powder, vitamin B1, B2, B5, B6, E and acetate esters, nicotinic acid amide as a nutritional supplement Oligosaccharides may be added, and other food additives may be added.

이상에서와 같이, 본 발명은 지방세포에서 SOCS-3 단백질의 발현을 억제하여 인슐린 저항성을 개선하며, 혈당강하 및 비만억제 효과가 있는 냉초 에탄올 추출물을 함유하는 약학 조성물, 발효유, 음료, 기능성 식품 등 대사증후군의 예방 및 개선 효과를 갖는 제품에 응용될 수 있다.As described above, the present invention improves insulin resistance by inhibiting the expression of SOCS-3 protein in adipocytes, pharmaceutical compositions containing cold grass ethanol extracts that have a hypoglycemic and anti-obesity effect, fermented milk, beverages, functional foods, etc. It can be applied to a product having the effect of preventing and improving metabolic syndrome.

이하 실시예를 통하여 본 발명을 보다 상세하게 설명한다. 그러나 다음의 실시예는 본 발명의 범위를 한정하는 것은 아니며, 본 발명의 기술적 사상의 범위 내에서 당업자에 의한 통상적인 변화가 가능하다.Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are not intended to limit the scope of the present invention, and ordinary changes by those skilled in the art are possible within the scope of the technical idea of the present invention.

<실시예 1>&Lt; Example 1 >

냉초 에탄올 추출물의 제조Preparation of cold ethanol extract

냉초는 뿌리와 줄기부분을 모아 건조시킨 후, 파쇄하고 단위 질량당(kg) 1 L의 50% 에탄올을 첨가하여 상온에서 7일 정도 반응시켜 추출액을 얻었다. 상기 추출액은 여과지에 거른 후 동결건조하여 분말화하여 냉초 에탄올 추출물을 제조하였다.Cold grass was collected by drying the roots and stems, and then crushed and added to 1 L of 50% ethanol per unit mass (kg) and reacted at room temperature for 7 days to obtain an extract. The extract was filtered on a filter paper and then lyophilized to powder to prepare a cold ethanol extract.

<실시예 2><Example 2>

냉초 에탄올 추출물을 이용한 약학적 조성물의 제조Preparation of pharmaceutical composition using cold ethanol extract

하기에 본 발명에 따른 냉초의 에탄올 추출물을 유효성분으로 함유하는 대사증후군 예방 및 치료용 약학조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, an example of the preparation of a pharmaceutical composition for preventing and treating metabolic syndrome containing cold ethanol extract of the present invention as an active ingredient will be described, but the present invention is not intended to be limited thereto.

산제의 제조Manufacture of powder

약전 제제총칙 중 산제의 제조방법에 따라 1포당 하기의 성분 함량으로 제조한다.According to the preparation method of powder in the Pharmacopoeia General Formulation, it is prepared in the following component content per packet.

냉초 에탄올 추출물(건조분말)...................... 300㎎Cold ethanol extract (dry powder) ...................... 300 mg

유당.............................................. 100㎎Lactose 100 mg

탈크.............................................. 10㎎Talc ........................................ 10mg

정제의 제조Manufacture of tablets

약전 제제총칙 중 정제의 제조방법에 따라 1정당 하기의 성분 함량으로 제조한다.According to the preparation method of tablets in the Pharmacopoeia General Formulation, it is prepared in the following component contents per tablet.

냉초 에탄올 추출물(건조분말)....................... 300㎎Cold ethanol extract (dry powder) ....... 300 mg

옥수수전분......................................... 100㎎Corn starch ........................... 100 mg

유당............................................... 100㎎Lactose ......................................... 100 mg

스테아린산 마그네슘................................ 2㎎Magnesium Stearate ................................................... 2mg

캅셀제의 제조Manufacture of capsules

약전 제제총칙 중 캅셀제의 제조방법에 따라 1캅셀당 하기의 성분 함량으로 제조한다.According to the preparation method of capsules in the pharmacopeia formulation, it is prepared in the following component content per capsule.

냉초 에탄올 추출물(건조분말)........................ 300㎎Cold ethanol extract (dry powder) ........ 300 mg

옥수수전분.......................................... 100㎎Corn starch ........................... 100 mg

유당................................................ 100㎎Lactose ... Mg

스테아린산 마그네슘................................. 2㎎Magnesium Stearate ......................................... 2 mg

액제의 제조Preparation of liquid

약전 제제총칙 중 액제제의 제조방법에 따라 액제 100㎖당 하기의 성분 함량으로 제조한다.According to the method for preparing a liquid formulation in the Pharmacopoeia General Formulation, it is prepared in the following component content per 100 ml of liquid formulation.

냉초 에탄올 추출물(건조분말).......................... 1gCold ethanol extract (dry powder) ....................... 1g

이성화당.............................................. 10gIsomerized sugar ......................................... 10g

만니톨................................................ 5gMannitol ......................................... 5 g

정제수................................................ 적량Purified water ......................................

<실시예 3><Example 3>

냉초 에탄올 추출물을 이용한 발효유의 제조Preparation of Fermented Milk Using Cold Ethanol Extract

유산균 배양액과 상기 실시예 1의 냉초 에탄올 추출물의 동결건조분말 및 혼합과즙시럽으로 구성된 발효유를 제조하는 방법은 다음과 같다.Method for producing a fermented milk consisting of a freeze-dried powder of the lactic acid bacteria culture medium and the cold ethanol extract of Example 1 and mixed fruit juice syrup is as follows.

유산균 배양액은 원유 95.36중량%와 탈지분유(또는 혼합분유) 4.6중량%를 교반하여 15℃에서의 비중은 1.0473~1.0475, 적정산도는 0.200~0.220%, pH는 6.65~6.70, 20℃에서의 브릭스(Brixo)는 16.3~16.5% 정도가 되도록 혼합하였다. 그런 다음, 이를 UHT 열처리(135℃에서 2초간 살균)하고 40℃로 냉각한 뒤, 스트렙토코커스 써모필러스(Streptococcus thermophilus)균과 유당분해효소(Valley laboratory, USA)를 각기 0.02중량%씩 첨가하고 6시간 동안 배양하여, BCP 배지에서의 총 유산균수가 1.0 × 109 cfu/㎖ 이상, 적정산도가 0.89~0.91%, pH는 4.55~4.65가 되도록 하여 제조하였다.The lactic acid bacteria culture medium was stirred at 95.36% of crude milk and 4.6% by weight of skim milk powder (or mixed milk powder), and the specific gravity at 15 ° C was 1.0473 to 1.0475, the titratable acidity was 0.200 to 0.220%, the pH was 6.65 to 6.70, and the brix at 20 ° C. (Brix o ) was mixed to 16.3 ~ 16.5%. Then, UHT heat treatment (sterilized at 135 ℃ for 2 seconds), cooled to 40 ℃, Streptococcus thermophilus bacteria and lactose (Valley laboratory, USA) each added 0.02% by weight Incubated for 6 hours, the total lactic acid bacteria in BCP medium was prepared by 1.0 × 10 9 cfu / ㎖ or more, the titratable acidity is 0.89 ~ 0.91%, pH is 4.55 ~ 4.65.

혼합과즙시럽은 액상과당 10중량%, 백설탕 3중량%, 갈색설탕 3중량%, 혼합과즙농축액(56 Brixo) 10중량%, 펙틴 0.1중량%, 후레쉬 후르츠 믹스 에센스 0.05중량% 및 정제수 73.85중량%를 30~35℃에서 교반하여 혼합한 후 UHT 열처리(135℃에서 2초간 살균)한 후 냉각하여 제조하였다.Mixed fruit syrup consists of 10% by weight liquid fructose, 3% by weight white sugar, 3% by weight brown sugar, 10% by weight mixed juice concentrate (56 Brix o ), 0.1% by weight pectin, 0.05% by weight fresh fruit mix essence and 73.85% by weight purified water After mixing by stirring at 30 ~ 35 ℃ UHT heat treatment (sterilized for 2 seconds at 135 ℃) was prepared by cooling.

상기의 방법으로 제조된 유산균 배양액 75중량%와 상기 실시예 1의 냉초 에탄올 추출물의 동결건조분말 0.1중량% 및 상기 방법으로 제조된 혼합과즙시럽 24.9중량%를 조합하여 150bar에서 균질한 후 10℃ 이하로 냉각하여 대사증후군 예방 및 치료 효능을 갖는 냉초 에탄올 추출물을 유효성분으로 함유하는 발효유를 제조하였다.75% by weight of the lactic acid bacteria culture medium prepared by the above method, 0.1% by weight of the freeze-dried powder of the cold ethanol extract of Example 1 and 24.9% by weight of the mixed fruit juice syrup prepared by the above method was homogeneous at 150 bar and then 10 ° C. or less. Cooled to prepare a fermented milk containing cold grass ethanol extract as an active ingredient having the effect of preventing and treating metabolic syndrome.

<실시예 4><Example 4>

냉초 에탄올 추출물을 이용한 음료의 제조Preparation of Beverage Using Cold Ethanol Extract

상기 실시예 1의 냉초 에탄올 추출물의 동결건조분말과 혼합과즙시럽으로 구성된 기능성 음료를 제조하는 방법은 다음과 같다.Method for producing a functional beverage consisting of a freeze-dried powder and mixed juice syrup of the cold ethanol extract of Example 1 is as follows.

혼합과즙시럽은 액상과당 10중량%, 백설탕 3중량%, 갈색설탕 3중량%, 혼합과즙농축액(56 Brixo) 10중량%, 펙틴 0.1중량%, 후레쉬 후르츠 믹스 에센스 0.05중량% 및 정제수 73.85중량%를 30~35℃에서 교반하여 혼합한 후 UHT 열처리(135℃에서 2초간 살균)한 후 냉각하여 제조하였다.Mixed fruit syrup consists of 10% by weight liquid fructose, 3% by weight white sugar, 3% by weight brown sugar, 10% by weight mixed juice concentrate (56 Brix o ), 0.1% by weight pectin, 0.05% by weight fresh fruit mix essence and 73.85% by weight purified water After mixing by stirring at 30 ~ 35 ℃ UHT heat treatment (sterilized for 2 seconds at 135 ℃) was prepared by cooling.

상기의 방법으로 제조된 혼합과즙시럽 29.9중량%와 상기 실시예 1의 냉초 에탄올 추출물의 동결건조분말 0.1중량% 및 멸균 정제수 70중량%를 조합하여 150bar에서 균질한 후 10℃ 이하로 냉각한 후 이를 유리병, 패트병 등 소포장 용기에 포 장하여 대사증후군 예방 및 치료 효능을 갖는 냉초 에탄올 추출물을 유효성분으로 함유하는 기능성 음료를 제조하였다.29.9% by weight of the mixed juice syrup prepared by the above method, 0.1% by weight of the lyophilized powder of the cold ethanol extract of Example 1 and 70% by weight of sterile purified water were homogenized at 150 bar, and then cooled to 10 ° C. or lower. Functional drinks containing cold ethanol extracts as effective ingredients were prepared by packaging them in small packaging containers such as glass bottles and plastic bottles to prevent and treat metabolic syndrome.

<실시예 5>Example 5

냉초 에탄올 추출물을 이용한 건강기능식품의 제조Preparation of health functional food using cold ethanol extract

상기 실시예 1의 냉초 에탄올 추출물의 동결건조분말 0.1중량%에 영양보조성분(비타민 B1, B2, B5, B6, E 및 초산에스테르, 니코틴산 아미드) 및 올리고당을 상기의 실시예 1의 냉초 에탄올 추출물의 동결건조분말 100중량부에 대하여 10중량부가 되도록 첨가하여 고속회전 혼합기에서 혼합하였다. 상기 혼합물에 멸균 정제수 10중량%를 첨가, 혼합하고 직경 1~2mm의 과립상으로 성형하였다. 상기 성형된 과립은 40~50℃의 진공건조기에서 건조시킨 후, 12~14 메쉬(mesh)를 통과시켜 균일하게 과립을 제조하였다. 상기와 같이 제조된 과립은 적당량씩 압출 성형되어 정제 또는 분말로 되거나 경질캡슐에 충전되어 경질캡슐제품으로 제조하였다.0.1 parts by weight of the freeze-dried powder of the cold ethanol extract of Example 1 to the nutritional supplements (vitamins B1, B2, B5, B6, E and acetate esters, nicotinic acid amide) and oligosaccharides of the cold ethanol extract of Example 1 10 parts by weight based on 100 parts by weight of the lyophilized powder was added and mixed in a high speed rotary mixer. 10% by weight of sterile purified water was added to the mixture, mixed, and molded into granules having a diameter of 1 to 2 mm. The molded granules were dried in a vacuum dryer at 40 to 50 ° C., and then passed through 12 to 14 meshes to uniformly prepare granules. The granules prepared as described above were extruded by appropriate amounts into tablets or powders or filled into hard capsules to produce hard capsule products.

<시험예 1><Test Example 1>

냉초 에탄올 추출물의 지방세포 SOCS-3 단백질 발현 저해효과Inhibitory Effects of Ethanol Extracts from Cold Water on Adipose Cell SOCS-3 Protein Expression

1-1 지방세포 SOCS-3 단백질 발현 확인1-1 Adipose Cell SOCS-3 Protein Expression

멸균된 6 well plate에 쥐(mouse)의 전구지방세포(3T3-L1 preadipocyte)를 미리 분화시켜 지방세포로 만들었다. 분화유도 10일 째인 완전히 분화된 지방세포에 인슐린을 1, 3, 5μg/mL의 농도별로 처리한 후 5시간 동안 37℃ CO2 배양기에서 배 양시키고 단백질을 추출하여 웨스턴블랏(western blot)을 통해 SOCS-3 단백질의 발현이 유도되었는지 확인하였다. Adipocytes were pre-differentiated into mouse progenitor cells (3T3-L1 preadipocytes) in sterile 6 well plates. On day 10 of differentiation, fully differentiated adipocytes were treated with insulin at concentrations of 1, 3, and 5 μg / mL, and then cultured in a 37 ° C. CO2 incubator for 5 hours, and proteins were extracted to obtain SOCS through western blot. It was confirmed that expression of -3 protein was induced.

그 결과를 나타낸 도 1에서 확인할 수 있는 바와 같이, 5μg/mL의 인슐린을 첨가하였을 때 SOCS-3 단백질이 발현됨을 확인 할 수 있었다.As can be seen in Figure 1 showing the results, it was confirmed that the expression of SOCS-3 protein when 5μg / mL of insulin was added.

1-2 냉초 에탄올 추출물의 지방세포 SOCS-3 단백질 발현 저해 확인Inhibition of Adipose Cell SOCS-3 Protein Expression by 1-2 Cold Ethanol Extracts

상기 시험예 1-1과 같이 상기 전구지방세포에 인슐린을 5μg/mL 처리하여 SOCS-3단백질을 발현을 유도시킨 후, 냉초 에탄올 추출물을 각각 50, 100, 200μg/mL 씩 농도별로 처리하여 실제로 SOCS-3 단백질의 발현이 저해되는지 확인하였다. Induction of SOCS-3 protein by treating insulin with 5μg / mL of the precursor adipocytes as in Test Example 1-1, followed by 50, 100, 200μg / mL of cold ethanol extract, respectively, by concentration of SOCS It was confirmed whether the expression of the -3 protein is inhibited.

한편, 상기 시험예 1-1과 같이 SOCS-3 단백질의 발현을 유도하고 인슐린만을 처리한 것을 대조군으로 하였다.On the other hand, induction of the expression of SOCS-3 protein as in Test Example 1-1 and treated with only insulin as a control.

그 결과를 도 2에 나타내었다.The results are shown in FIG.

도 2에서 확인할 수 있는 바와 같이, 냉초 에탄올 추출물을 100μg/mL 이상 처리한 경우에 SOCS-3 단백질의 발현이 저해됨을 알 수 있는데, 이에 따라 SOCS-3 단백질에 의해 분해가 일어나는 인슐린 수용체 하위체(Insulin receptor subunint-1, IRS-1)의 발현이 냉초 에탄올 추출물을 처리한 지방세포에서는 개선된 것을 확인하였다.As can be seen in Figure 2, it can be seen that the expression of SOCS-3 protein is inhibited when the cold ethanol ethanol extract 100μg / mL or more treatment, according to the insulin receptor subtype that is degraded by SOCS-3 protein ( Insulin receptor subunint-1 (IRS-1) expression was improved in adipocytes treated with cold ethanol extract.

<시험예 2><Test Example 2>

냉초 에탄올 추출물의 인슐린 저항성 개선효과Effect of Cold Ethanol Extract on Insulin Resistance

2-1 공복 혈당측정2-1 Fasting Blood Glucose Measurement

본 발명에 따른 냉초 에탄올 추출물의 인슐린 저항성 개선효과를 확인하기 위해 고지방식이를 이용한 동물실험을 실시하였다. 실험동물은 C57BL/6 쥐(mice)로 3주령인 수컷을 1주일동안 고지방 식이를 공급하면서 적응시킨 후 이용하였다. 모든 시험군의 쥐는 7마리씩 완전 임의배치 하였으며 시험군은 총 3군으로 각 시험군에 투여한 사료의 조성비는 표 1과 같다. 고지방식이는 Research diets사의 D12451(45% fat, 5.252cal/g)을 이용하였으며, 고지방식이만을 실시한 실험군(고지방식이군)과 정상식이만을 실시한 실험군(정상식이군)을 대조군으로 하고, 실험군의 사료에 첨가된 냉초 에탄올 추출물은 동결건조하여 분말화한 후 고지방식이에 1%(w/w) 농도로 혼합하여 1% 냉초투여군으로 하였다.In order to confirm the effect of improving the insulin resistance of the cold ethanol extract according to the present invention was carried out animal experiments using a high-fat diet. The experimental animals were C57BL / 6 mice, which were used after adapting a 3 week old male with a high fat diet for 1 week. Seven rats of all test groups were completely randomized and the test groups consisted of three groups. The high-fat diet was D12451 (45% fat, 5.252 cal / g) from Research diets. The experimental group (high-fat diet group) and the normal diet-only test group (normal diet group) were used as controls. Cold ethanol extract added to the feed was lyophilized and powdered, and then mixed with a high fat diet at a concentration of 1% (w / w) to make a 1% cold grass administration group.

총 4주 동안 실험 식이를 투여하며 1주일에 2회 간격으로 체중과 사료 섭취량을 측정하였다. 4주간의 식이 투여 후 실험동물을 6시간 동안 절식시키고 공복혈당을 측정하였다.The experimental diet was administered for a total of four weeks, and body weight and feed intake were measured at two intervals per week. After 4 weeks of dietary administration, the experimental animals were fasted for 6 hours and fasting glucose was measured.

그 결과를 표 1에 나타내었다.The results are shown in Table 1.

표 1에서 확인할 수 있는 바와 같이, 1% 냉초투여군이 고지방식이군에 비하여 유의적으로 공복혈당이 낮아진 것을 확인 할 수 있었다.As can be seen in Table 1, the 1% cold grass administration group was confirmed that the fasting blood sugar was significantly lower than the high-fat diet group.

2-2 인슐린 민감성 측정2-2 Insulin Sensitivity Measurement

또한 상기 시험예 2-1의 4주간 실험식이를 투여한 쥐들(고지방식이군, 정상식이군, 1% 냉초투여군)의 인슐린 민감성을 측정하기 위해 공복상태에서 당부하시험을 하였다. 6시간 동안 공복을 유지한 실험동물에게 2g/kg농도의 포도당(glucose)을 각각 경구투여하고 30분씩 2시간 동안 혈당의 변화를 측정하였다. In addition, the glucose-load test was performed in a fasted state to measure insulin sensitivity of rats (high-fat diet, normal diet, 1% cold grass administration group) administered the experimental diet for 4 weeks of Test Example 2-1. 6 hours of fasting to the test animals were administered orally administered glucose (glucose) concentration of 2g / kg concentration for 30 minutes each 2 hours to measure the change in blood glucose.

그 결과를 도 3에 나타내었다.The results are shown in Fig.

도 3에서 확인할 수 있는 바와 같이, 고지방식이를 먹은 쥐는 혈당이 높아지고 120분이 지나도 공복시 혈당으로 낮아지지 않는 등 체내 혈당조절이 정상식이군 보다 늦게 일어남을 볼 수 있는 반면, 냉초의 에탄올 추출물을 고지방식이에 섞어 먹인 실험군(1% 냉초 투여군)은 정상식이군과 마찬가지로 공복혈당이 낮으며 당부하 후 일정시간이 지나면 공복혈당으로 조절되는 것을 확인할 수 있었다.As can be seen in Figure 3, rats fed a high-fat diet, high blood sugar and 120 minutes after fasting blood sugar, such as fasting blood sugar control can be seen later than normal diet group, while cold ethanol extract high-fat diet The experimental group fed (1% cold grass administration group) was mixed with low fasting blood sugar as in the normal diet group, and after a certain period of time after the glucose load was confirmed to be controlled to fasting blood glucose.

이와 같이 냉초 에탄올 추출물을 일정기간 이상 복용할 경우 혈당이 낮아지고, 음식물 섭취와 같은 당부하가 있었을 때에도 빠르게 혈당이 안정화되는 사실을 통하여 본 발명의 냉초의 에탄올 추출물을 혈당 강하제로의 이용을 고려할 수 있음을 의미한다.As such, when the cold ethanol extract is taken for a certain period of time, the blood sugar is lowered, and even when there is a sugar load such as food intake, the blood sugar is stabilized rapidly. Thus, the use of the cold ethanol extract of the present invention may be considered as a hypoglycemic agent. It means that there is.

Figure 112008082288088-pat00001
Figure 112008082288088-pat00001

<시험예 3><Test Example 3>

냉초 에탄올 추출물의 비만억제효과Anti-obesity Effect of Cold Ethanol Extracts

본 발명에 따른 냉초 에탄올 추출물의 비만억제효과를 확인하기 위해 시험예 2의 동물실험에서 4주간 1주에 2회 간격으로 체중변화량과 4주 후 실험동물을 개복하여 부고환 주변에 형성된 지방조직의 양을 측정하였다.In order to confirm the anti-obesity effect of the cold ethanol extract according to the present invention, the weight change and the amount of fat tissue formed around the epididymis after 4 weeks in the animal experiment of Test Example 2 every two weeks for 4 weeks Was measured.

그 결과를 표 2에 나타내었다.The results are shown in Table 2.

표 2에서 확인할 수 있는 바와 같이, 고지방식이군은 정상식이군에 비해 체중 증가량이 2배 정도 늘었는데 반하여, 1% 냉초투여군은 정상식이군과 비슷한 체중 증가량을 보였다. 또한, 정상식이군에 비해 고지방식이군은 지방량이 2.5배 가량 증가하였으나 1% 냉초투여군은 고지방식이를 하였음에도 불구하고 고지방식이이군에 비하여 지방량의 증가가 줄어들었다. As can be seen in Table 2, the high-fat diet group gained twice as much weight as the normal diet group, whereas the 1% cold grass group showed similar weight gain as the normal diet group. In addition, the fat diet of the high-fat diet group increased 2.5 times compared to the normal diet group, but the 1% cold grass group fed the high-fat diet, but the increase of fat mass decreased compared to the high-fat diet group.

이와 같은 사실을 통하여 냉초 에탄올 추출물은 체지방 증가 억제와 체중 증가 억제효능이 있어 최종적으로 비만억제효능이 우수함을 알 수 있었다.Through these facts, the cold ethanol extract was found to have an effect of inhibiting body fat increase and weight gain and finally having an excellent anti-obesity effect.

Figure 112008082288088-pat00002
Figure 112008082288088-pat00002

도 1은 쥐의 지방세포(3T3-L1 adipocyte)에 인슐린을 농도별로 처리하여 SOCS-3 단백질의 발현이 유도되는지 확인하는 단백질 분석 사진이다.Figure 1 is a protein analysis picture to determine whether the expression of SOCS-3 protein is induced by treating the concentration of insulin in rat fat cells (3T3-L1 adipocyte).

도 2는 쥐의 지방세포에서 인슐린과 함께 냉초 에탄올 추출물을 처리하여 SOCS-3 단백질의 발현이 저해되고 IRS-1의 발현이 개선되는 것을 나타낸 단백질 분석 사진이다.2 is a protein analysis picture showing that the expression of SOCS-3 protein is inhibited and the expression of IRS-1 is improved by treating cold grass ethanol extract with insulin in mouse fat cells.

도 3은 포도당 경구 투여 후 실험동물의 시간에 따른 혈당변화를 나타낸 그래프이다.3 is a graph showing the change in blood glucose with time of the experimental animal after oral administration of glucose.

Claims (8)

삭제delete 삭제delete 삭제delete 지방세포의 SOCS-3 단백질의 발현을 억제함으로써 인슐린 저항성을 개선하는 효능을 갖는 냉초 에탄올 추출물을 유효성분으로 함유하는 것을 특징으로 하는 당뇨 예방 및 치료용 약학조성물.A pharmaceutical composition for preventing and treating diabetes, characterized in that it contains cold ethanol extract having an effect of improving insulin resistance by inhibiting the expression of SOCS-3 protein in adipocytes as an active ingredient. 삭제delete 삭제delete 삭제delete 체지방 및 체중 증가를 억제하는 효능을 갖는 냉초 에탄올 추출물을 유효성분으로 함유하는 것을 특징으로 하는 비만 예방 및 치료용 약학조성물.A pharmaceutical composition for the prevention and treatment of obesity, characterized in that it contains a cold grass ethanol extract having an effect of inhibiting body fat and weight gain as an active ingredient.
KR1020080119631A 2008-11-28 2008-11-28 Cold grass extract having an effect of improving insulin resistance and a product containing the same as an active ingredient KR101047796B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020080119631A KR101047796B1 (en) 2008-11-28 2008-11-28 Cold grass extract having an effect of improving insulin resistance and a product containing the same as an active ingredient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020080119631A KR101047796B1 (en) 2008-11-28 2008-11-28 Cold grass extract having an effect of improving insulin resistance and a product containing the same as an active ingredient

Publications (2)

Publication Number Publication Date
KR20100060857A KR20100060857A (en) 2010-06-07
KR101047796B1 true KR101047796B1 (en) 2011-07-07

Family

ID=42361719

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020080119631A KR101047796B1 (en) 2008-11-28 2008-11-28 Cold grass extract having an effect of improving insulin resistance and a product containing the same as an active ingredient

Country Status (1)

Country Link
KR (1) KR101047796B1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102342058B1 (en) 2020-02-07 2021-12-22 대한민국 Pharmaceutical composition for preventing or treating diabetes and food composition having the same
KR102500985B1 (en) * 2022-10-06 2023-02-20 박민준 Manufacturing method of instant rice for lunch box showing anti-obesity effect

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
논문1:Chem. Pharm. Bull *
논문1:Chem. Pharm. Bull*

Also Published As

Publication number Publication date
KR20100060857A (en) 2010-06-07

Similar Documents

Publication Publication Date Title
US10646498B2 (en) Composition for preventing, alleviating or treating muscle diseases or improving muscular function
KR20160041138A (en) Composition for Prevention or Treatment of Obesity Comprising Tenebrio molitor larva extract or Tenebrio molitor larva suspension
KR101579845B1 (en) Composition that comprising fenugreek extract or compound including fenugreek extract for preventing and improving the andropause or male menopause symptom which involves lethargy, hypotrophy, muscle weakness, increasing visceral fat, tiredness and stress, by increasing testosterone level, endurance, muscle mass and decreasing visceral fat and improving blood lipid composition, number of sperm and activation of sperm
EP3326638A1 (en) Pharmaceutical composition for preventing or treating il-6-mediated diseases comprisingrosa rugosa
JP7007663B2 (en) Kuro-moji extract
KR20160141027A (en) Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder
KR20200140749A (en) Composition for improvement, treatment or prevention of muscular disorders, or improvement of muscular functions comprising Cudrania tricuspidata
KR101047796B1 (en) Cold grass extract having an effect of improving insulin resistance and a product containing the same as an active ingredient
KR102203657B1 (en) A composition comprising the complex extract for antiobesity of women
KR20190053108A (en) A composition comprising the complex extract for antiobesity of men
KR20200022660A (en) Composition for preventing or treating of fatty liver, hyperlipemia or obesity comprising mixed extracts
KR102470155B1 (en) Oral composition for reducing body weight or body fat comprising Artemisia dracunculus and Taraxacum officinale
KR20150031373A (en) Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component
JP2018135311A (en) Fgf21 expression promoting composition
KR101336068B1 (en) Anti-diabetes composition comprising oriental herbal extracts and fractions
KR101089314B1 (en) Composition containing euphobiasteroid for prevention, treatment or improvement of obesity
KR101181347B1 (en) Composition for the prevention and treatment of lipid-related cardiovascular disease or obesity containing the extracts of Dictamnus dasycarpus as active ingredient
KR101018404B1 (en) Compositions for reducing cholesterol comprising extracts of Vaccinium oldhami Miquel leaf as an active ingredient
CN111887332A (en) Konjak chocolate capable of dispelling effects of alcohol, protecting liver and benefiting intestines and preparation method thereof
KR20160059152A (en) Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component
KR101629642B1 (en) Food composition, pharmaceutical composition, animal medicine and feed composition against fatty liver with piperlongumine
KR101559655B1 (en) Composition comprising myricetin for inhibition of pancreatic lipase
KR102633488B1 (en) Composition for improvement, prevention or treatment of muscular disorders, or improvement of muscular functions comprising Korean mint extract or tilianin
KR100518686B1 (en) Extract of herb for promoting release of growth hormone
KR101241338B1 (en) Composition for the prevention and treatment of lipid-related cardiovascular disease or obesity containing extracts of Polygonum aviculare as active ingredient

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20140701

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20150701

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20160704

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20170704

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20180702

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20190701

Year of fee payment: 9